Latest Biotech News

Revolution Medicines said its Phase 3 study of daraxonrasib in advanced pancreatic adenocarcinoma produced a median survival of 13.2 months versus 6.7 months with standard chemotherapy, delivering...

Kailera Therapeutics’ upsized IPO raised $625 million to fund global clinical trials across its pipeline of injectable and oral obesity drug candidates, extending investor focus on anti-obesity...

The Breakthrough Prize Foundation awarded Life Sciences prizes to pioneering teams behind landmark gene therapies, including work connected to a US-available retinal blindness treatment and...

Researchers reported an adenine base editing approach that corrects a cryptic splice mutation (IVS4+919, G>A) underlying cardiac-type Fabry disease in cells, according to a study published in Gene...

A Nature Communications study used wastewater-based epidemiology to detect the emergence of clinically significant and drug-resistant Candida auris strains in healthcare settings, mapping how...

Two separate policy updates pointed to a more enforcement-led FDA posture affecting both review and promotion of therapeutics. One report described an FDA budget proposal including policy “wish...

Scientists reported an AAV6.2 gene delivery system designed to drive localized expression of immunomodulatory cytokines in mouse lungs during inflammatory challenges, without detectable peripheral...

10x Genomics launched its Atera spatial platform at AACR 2026, positioning it as whole-transcriptome spatial biology at scale intended to reduce trade-offs seen in existing spatial tools. In...

UCB agreed to buy Neurona for up to $1.2 billion, aiming to add a potentially one-off seizure cell therapy to its primarily small-molecule portfolio. The transaction is intended to diversify...

Bruker announced leadership transitions within its BioSpin organization, with Falko Busse set to transition out of executive officer and BioSpin Group president roles around May 1, 2026. Jackson...

Revolution Medicines’ daraxonrasib, a KRAS-focused oral therapy, delivered a survival benefit in a Phase 3 pancreatic cancer readout highlighted by STAT+. In advanced pancreatic adenocarcinoma,...

Roche is laying additional groundwork for European regulators on its Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec). The company announced a further global Phase...

UCB agreed to acquire Neurona Therapeutics for up to $1.2 billion, positioning the Belgian drugmaker to move beyond its small-molecule core into seizure cell therapy. The deal adds an...

AACR spotlighted dual-payload antibody-drug conjugates as a next-generation modality as the field pushes into clinical translation. The Biocentury product development coverage cited more than 40...

Researchers reported that wastewater-based epidemiology can detect the emergence of clinically significant, drug-resistant Candida auris strains in healthcare settings. A study by Chang, Moshi,...

A Gene Therapy paper described adenine base editing (ABE) that corrects a cryptic splice mutation linked to cardiac-type Fabry disease in cells. Researchers targeted the IVS4+919 G>A mutation...

Researchers reported results from a clinical trial testing regulatory dendritic cells (DCreg) to manage immune response after living-donor liver transplantation. The approach combines DCreg...

10x Genomics unveiled Atera, a new spatial platform positioned to deliver whole-transcriptome spatial biology at scale. The company presented the instrument at AACR, describing a design meant to...

Alamar Biosciences priced its IPO at $17 per share, selling 12,937,500 shares and raising about $220 million in gross proceeds. Shares jumped in early trading after beginning to trade on Nasdaq...

Kailera Therapeutics priced an upsized US IPO to raise $625 million, with the proceeds earmarked for clinical development of its obesity drug candidates. Coverage notes the company’s obesity-first...